Aurinia Pharmaceuticals Inc. Aktie News

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14...

GENEVA--(BUSINESS WIRE)--Lucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following letter to Aurinia shareholders: May 7, 2024 Fellow Shareholders, As a shareholder of Aurinia since 2020, I have grown increasingly worried about the Company's trajectory and am disappointed in the Boa...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference.

AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 whether in AUPH's hands, or externally if the drug is out-licensed. AUPH bought back 3.4M shares through April 30, at an average price of $5.37 per share.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Farzin Haque - Jefferies Stacy Ku - TD Cowen Joseph Schwart...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheu...

Aurinia Pharmaceuticals Inc. full-year 2023 sales of Lupkynis increased by 53% year over year to $158.5 million. Updated label provides several advantages for sales of Lupkynis going forward, like no need for monthly kidney monitoring 1-year after treatment, lactation note for women and display of 3-year efficacy. Besides label expansion of Lupkynis, other shareholder generating measures enacte...